000534Wedge CorporationSZSE

Wedge Industrial Co., Ltd.

万泽股份

000534

Shenzhen Stock Exchange

BoardMain Board of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ListedJanuary 10, 1994
Websitewww.wedgeind.com
IR Emailwzgf0534@163.com
Phone(+86)-0755-83260208、(+86)-0755-83241679
Sourcecninfo.com.cn
Address1F, Yunding Cuifeng podium building, No. 2016 Fuqiang Road, Huanggang Community, Futian Street, Futian District, Shenzhen

Company Overview

Wedge Industrial Co., Ltd. is a manufacturing company listed on the Shenzhen Stock Exchange since 1994. The company specializes in the research, development, production, and sales of probiotic products and high-temperature alloys. It operates through its wholly-owned subsidiary, Inner Mongolia ShuangQi Pharmaceutical Co., Ltd., which focuses on human microecological systems, particularly in digestion and gynecology. Wedge Industrial's main business lines include probiotic products, such as the clinically used "Golden Bifid" and "DingJunSheng," as well as a range of dietary supplements and health products. The company has established a strong market presence through a nationwide marketing system and collaborations with over 3,000 hospitals and numerous pharmacies. In the high-temperature alloy sector, Wedge Industrial develops precision cast blades and high-temperature alloy materials, leveraging a skilled team with significant expertise in material science. The company is recognized for its comprehensive capabilities in high-temperature alloy technology, serving industries such as aviation and gas turbines.

AI-generated from company disclosures and CNInfo data.

Company Profile

(I) Probiotic products business 1. The company has been deeply involved in the field of microecology for 30 years and has formed a solid technological foundation, which is reflected in: ① with a high standard production quality system, possessing advanced pharmaceutical machinery and equipment such as fermentation, freeze-drying, tablet pressing, and blister packaging in China, having built the largest standardized GMP factory with high automation in the domestic live bacterial drug industry, and establishing a strict drug production quality management system; ② we have an experienced and specialized team of experts in the research and production of microbial ecological drugs, and have established a leading microbial strain library in China, possessing advanced strain screening and storage technologies; ③ possessing independent intellectual property rights and technological barriers, engaging in multiple national-level research and development projects, and obtaining multiple scientific and technological achievements and awards. 2. The company boasts a nationwide omnichannel marketing system and mature commercial transformation capabilities, which are reflected in: ① establishing an in-hospital and out-of-hospital marketing system; ② in-depth cooperation with leading commercial companies such as China National Pharmaceutical Group, China Resources Pharmaceutical Commercial Group, Shanghai Pharmaceutical Group, Jiuzhou Tong Pharmaceutical Group, and Guangzhou Pharmaceutical; ③ we have established cooperation with over 3000 accredited hospitals and more than 100,000 terminal social pharmacies across the country; ④ we have a team of over a thousand people for in-hospital, out-of-hospital, academic promotion, and commercial activities (including self-built and service provider teams). 3. The company has abundant expert resources and has been conducting scientific evidence-based research for a long time, which is reflected in: ① building a national three-level academic system, establishing cooperative relationships with academic groups such as the Chinese Medical Association, the Chinese Physicians Association, the Chinese Preventive Medicine Association, the China Pharmacists Association, the Chinese Pharmaceutical Association, and the China Non-prescription Drugs Association, and carrying out various national, provincial, municipal, and hospital-level academic activities; ② deep scientific research cooperation with renowned experts from top-tier hospitals, comprehensive universities, and microbiology research institutes in China; ③ we have conducted extensive high-level evidence-based research and collaborated with numerous well-known tertiary hospitals in China to develop clinical research for "Golden Bifid" and "DingJunSheng", promoting the integration of microecological diagnosis and treatment solutions into industry consensus and disciplinary guidelines. (II) High temperature alloy business 1. The company is one of the few private enterprises in China capable of developing the entire process from high-temperature alloy material research and development to component manufacturing. The core team of the company's high-temperature alloy is composed of several high-end talents who have engaged in material science and engineering application research in the aviation engine and gas turbine industries, including 5 experts specially appointed at the national level and 5 high-level talents at the municipal level. The proportion of doctoral and master's degree talents exceeds 40%, forming one of the few research and development teams in China's high-temperature alloy field that have achieved international first-class standards in aviation engine high-temperature alloy materials and their applications. It has been successively rated as a provincial and municipal innovation and entrepreneurship team, and possesses relatively comprehensive high-temperature alloy full-process technical capabilities in areas such as material research and development, simulation, precision casting, and powder metallurgy. 2. The company has established a complete research, development, and testing system, equipped with a full suite of equipment for master alloy melting, powder preparation, casting and molding, and product physicochemical testing. We have solved multiple key technological challenges, developed multiple high-temperature alloy materials with proprietary intellectual property rights, secured multiple patents related to the high-temperature alloy business, and established long-term stable cooperative relationships with several domestic research institutes and enterprises. 3. The company has mastered advanced technologies in the production of high-temperature master alloys, high-temperature alloy powders, precision-cast blades, powder discs, and other hot-end components. Utilizing its independently developed database, along with the full-process simulation software system WeICME+AI technology, the company has established a technology system for ultra-high purity melting of high-temperature alloys and precision casting of turbine blades without excess. The company's products, including directional, single-crystal, and equiaxed-crystal blades, as well as powder turbine discs, have been successfully applied in various models of aircraft engines, gas turbines, and other equipment, and the company possesses the engineering capability for mass production.

64 announcements tracked· Last: August 20, 2026

Key Financials

As of 2026-08-15T00:00:00.000+00:00
Revenue¥666.6M
Net Profit¥125.4M
ROE6.70%
Debt Ratio57.69%
Monetary Funds¥564.2M
Receivables¥710.8M
Total Shares509.5M

Announcements

64 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.